» Articles » PMID: 15599839

Superiority of Big Endothelin-1 and Endothelin-1 over Natriuretic Peptides in Predicting Survival in Severe Congestive Heart Failure: a 7-year Follow-up Study

Overview
Journal J Card Fail
Date 2004 Dec 16
PMID 15599839
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Plasma concentrations of atrial and brain natriuretic peptides (ANP, BNP), of their N-terminal pro-peptides, of endothelin-1 (ET-1), and big endothelin-1 (big ET-1) have diagnostic and prognostic significance in congestive heart failure (CHF). However, their respective values as a predictor of survival remain controversial and have never been directly compared in severe CHF.

Methods And Results: We analyzed, in 47 patients with severe CHF (New York Heart Association [NYHA] class III to IV; age 66 +/- 8 years, ejection fraction 20 +/- 6%), the prognostic performance of a panel of neurohormones and assays (N-terminal pro-ANP 1-25, 68-98 by radioimmunoassay [RIA], and 1-98 by enzyme-linked immunosorbent assay [ELISA], BNP by RIA and immunoradiometric assay [IRMA], N-terminal pro-BNP by Elisa, ET-1 by RIA, and big ET-1 by RIA and Elisa. Data were compared with 40 patients with mild to moderate CHF [NYHA I-II] and 30 healthy subjects. After a follow-up of 81 +/- 15 months, there were 34 deaths and 1 heart transplant. All neurohormones were significantly higher at baseline in patients with severe than in mild to moderate CHF or healthy subjects (all P < .001). Although all neurohormones but BNP IRMA were significant predictors of survival in univariate analysis, only big ET-1 RIA and ET-1 were independent predictors of survival (improvement chi(2): 7.5 and 4.6, P < .01 and P < .05). Using medians as cutpoints of big ET-1 RIA and ET-1, 2 severe CHF populations were defined with a different outcome (5-year survival: 55 versus 18%, P < .01).

Conclusions: Big ET-1 and ET-1 are strong independent predictors of survival in patients with severe CHF and better for this purpose than natriuretic peptides or their pro-peptides. These markers allow easily to identify a population with a very high risk mortality eligible for more aggressive therapies.

Citing Articles

Anesthetic Management of Patients with Dilated Cardiomyopathy Undergoing Noncardiac Surgery.

Li M, Huang H Medicina (Kaunas). 2023; 59(9).

PMID: 37763685 PMC: 10533037. DOI: 10.3390/medicina59091567.


Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?.

Dmour B, Costache A, Dmour A, Huzum B, Duca S, Chetran A Diagnostics (Basel). 2023; 13(13).

PMID: 37443671 PMC: 10340204. DOI: 10.3390/diagnostics13132277.


Big Endothelin-1 as a Predictor of Reverse Remodeling and Prognosis in Dilated Cardiomyopathy.

Feng J, Liang L, Chen Y, Tian P, Zhao X, Huang B J Clin Med. 2023; 12(4).

PMID: 36835899 PMC: 9967115. DOI: 10.3390/jcm12041363.


Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers.

Borovac J, DAmario D, Bozic J, Glavas D World J Cardiol. 2020; 12(8):373-408.

PMID: 32879702 PMC: 7439452. DOI: 10.4330/wjc.v12.i8.373.


Reappraisal of Inflammatory Biomarkers in Heart Failure.

Chaikijurajai T, Tang W Curr Heart Fail Rep. 2020; 17(1):9-19.

PMID: 31916187 PMC: 7017677. DOI: 10.1007/s11897-019-00450-1.